Asian Journal of Cardiology Research

Toxic or Septic Myocarditis in a Patient Suffering from Aplastic Anemia

Karim Mounaouir *

Cardiology Division, Ibn Rochd University Hospital, Casablanca 20250, Morocco.

Mohammed Nachid

Cardiology Division, Ibn Rochd University Hospital, Casablanca 20250, Morocco.

Ali El Jazouli

Cardiology Division, Ibn Rochd University Hospital, Casablanca 20250, Morocco.

Meryem Haboub

Cardiology Division, Ibn Rochd University Hospital, Casablanca 20250, Morocco.

Arous Salim

Cardiology Division, Ibn Rochd University Hospital, Casablanca 20250, Morocco.

Ghali Bennouna

Cardiology Division, Ibn Rochd University Hospital, Casablanca 20250, Morocco.

Abdenasser Drighil

Cardiology Division, Ibn Rochd University Hospital, Casablanca 20250, Morocco.

Rachida Habbal

Cardiology Division, Ibn Rochd University Hospital, Casablanca 20250, Morocco.

*Author to whom correspondence should be addressed.

---

Abstract

The present case report highlights about Toxic or septic myocarditis in a patient suffering from aplastic anemia. A 21 years old female patient, without any cardiovascular risk factor, suffering from Aplastic Anemia, admitted initially for feverish neutropenia for which she received adequate antibiotherapy followed by Thymoglobulin® (anti-thymocyte globulin (rabbit)), which is an immunosuppressive agent used in treatment of Aplastic Anemia. Adverse cardiovascular reactions that have been reported in association with ATG include myocarditis, “cardiac irregularity,” chest pain, hypertension, hypotension, tachycardia, and bradycardia.

Keywords: Toxic myocarditis, septic myocarditis, aplastic anemia, myocarditis, chest pain, electrocardiogram, cardiac enzymes, cardiac magnetic resonance imaging, drug reactions.

---

---

---

References

Pfizer Inc. Atgam (lymphocyte immune globulin, antithymocyte globulin [equine] sterile solution) 2011.

Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101:1644–1655.

Zaky A, Deem S, Bendjelid K, Treggiari MM. Characterization of cardiac dysfunction in sepsis: An ongoing challenge. Shock. 2014;41:12–24. DOI: 10.1097/SHK.0000000000000065

Pulido JN, Afessa B, Masaki M, Yuasa T, Gillespie S, et al. Clinical spectrum, frequency, and significance of myocardial dysfunction in severe sepsis and septic shock.Mayo Clin Proc. 2012;87:620–628. DOI: 10.1016/j.mayocp.2012.01.018

Landesberg G, Jaffe AS, Gilon D, Levin PD, Goodman S, Abu-Baih A, Beeri R, Weissman C, et al. Troponin elevation in severe sepsis and septic shock: The role of left ventricular diastolic dysfunction and right ventricular dilatation*. Crit Care Med. 2014;42:790–800.

DOI: 10.1097/CCM.0000000000000107

Raza F, Anwer F, et al. Myocarditis in aplastic anemia: A rare complication. Cureus. 2020;12(10):e10756.

Samanta S, Samanta S, Mishra TS, et al. Aplastic anemia presenting as fulminant myocarditis: a case report and review of the literature. J Med Case Rep. 2018;12(1):175.

Saini H, Kumar P, Singh S, et al. Septic myocarditis as a presenting manifestation of aplastic anemia. J Pediatr Hematol Oncol. 2019;41(4):e245-e248. DOI: 10.1097/MPH.0000000000001354